No Sign of Slowdown in Biotech M&A
High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.
Jeremy Glaser: For Morningstar, I'm Jeremy Glaser. Six Morningstar equity analysts were recently named by the Wall Street Journal as Best on the Street. I'm here with Lauren Migliore. She was named as one of the best biotech analysts, and we are going to talk a little bit about the biotech industry and her favorite pick in that field right now.
Lauren, thanks for joining me.
Jeremy Glaser does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.